Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study

A legfontosabb adatok

Ki végzi
Novartis Pharmaceuticals
Hol
East Hanover (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
2517 fő vett részt
Kezdés
2021. júl. 14.
Befejezés
2024. máj. 17.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2025. május 28.

Ki vehet részt

Életkor
15 év – 90 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 12 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients with:; At least one confirmed diagnosis of AA registered during the baseline period, or; At least one confirmed diagnosis of idiopathic thrombocytopenic purpura (International Classification of Diseases, 10th Revision [ICD10] code: D69.3) registered before the index date and at least one confirmed diagnosis of AA during the follow-up period
  • Had at least 6 months of continuous enrolment prior to the index date; Confirmed diagnosis was defined as having ≥1 inpatient or ≥2 outpatient claims with a relevant ICD-10 code and without any doubtful flag; Continuous enrolment (being continuously followed in the database) was defined as having at least one claim every semester
  • Had at least one confirmed diagnosis of AA registered before the index date,
  • Had at least one procedure for any type of transfusion such as red blood cell transfusion, platelet transfusion, or granulocyte transfusion registered during the baseline period or within 4 weeks after the index date,
  • Had at least 6 months of continuous enrolment prior to the index date,
  • Had at least a 6-month follow-up period

Ki nem vehet részt

  • Not receiving ATG, CSA, ETB or romiplostim (ROM) during the selection period,
  • Not receiving ATG, CSA, ETB or ROM during the selection period,
  • Had a diagnosis of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelofibrosis, other hematological malignancies, or cataract before the index date; Inclusion and exclusion criteria for the effectiveness population:
  • Had a diagnosis of AML, CMML or other hematological malignancies before the index date
  • Had at least one prescription of ATG, CSA, ETB or ROM before the index date,

Egyéb feltételek

  • Inclusion and exclusion criteria for the safety population:

Helyszínek itt: Egyesült Államok

  • NovartisEast Hanover, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The main goal of this study was to investigate the effectiveness and safety of eltrombopag (ETB) when compared to other treatments in Japanese aplastic anemia (AA) patients using data from the Medical Data Vision (MDV) hospital-based database.

A vizsgálat 2 csoportja

  • Anatomical Therapeutic Chemical (ATG)-free Cohort

    Japanese patients with AA from the MDV database who received treatment with ciclosporin A (CSA) alone, ETB alone, or a combination of CSA and ETB.

  • ATG-Inclusive Cohort

    Japanese patients with AA from the MDV database who received one of the following treatment combinations: CSA and ATG or CSA and ETB and ATG.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Retrospective Medical Claims Database Study (Eltrombopag for Aplastic Anemia)
A regiszteradat frissítve
2025. május 28.